
improved therapeutic windows, particularly when lipophilic payloads are included in the ADC. Therefore, there is a continuing need for effective treatments of, for example, diseases using agents in cyclodextrin protein drug conjugates.

SUMMARY


[0007] Provided herein are compounds useful, for example, for the treatment of diseases, conditions, and disorders including, without limitation, metabolic diseases, proliferative diseases, and other diseases and conditions.

[0007a] In one aspect, the present disclosure relates to a compound or a pharmaceutically acceptable salt thereof, wherein

(i) the compound is according to formula (**Ib1**) or (**Ib2**):



or




,


(Ib1) **(Ib2)**

or


(ii) the compound is according to a formula selected from:




,



,





, and


;

or a triazole linkage regioisomer thereof;

wherein **BA** is an antibody or antigen binding fragment thereof;

LL is a trivalent linker that includes


or

;

SP is absent or is a spacer group residue selected from C_{1-6} alkylene, -NH-, -C(O)-, and $-(CH_2-CH_2-O)_e$, $-NH-CH_2-CH_2-(-O-CH_2-CH_2)_e-C(O)-$, and combinations thereof;

e is an integer from 0 to 4; **n** is an integer from 1 to 30; and

PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator.


[0008] In one example, set forth herein, is a compound or a pharmaceutically acceptable salt thereof, including: a protein linked to at least one payload moiety and linked to at least one cyclodextrin moiety via a covalent linker, wherein said covalent linker is bonded directly or indirectly to each of the binding agent, the payload moiety, and the cyclodextrin moiety.

[0009] In one example, set forth herein, is a compound or a pharmaceutically acceptable salt thereof, including: a binding agent linked to at least one payload moiety and linked to at least one cyclodextrin moiety via a covalent linker, wherein said covalent linker is bonded directly or indirectly to each of the binding agent, the payload moiety, and the cyclodextrin moiety.

[0010] In another example, set forth herein, is a compound, including: a reactive group linked to at least one payload moiety and linked to at least one cyclodextrin moiety via a covalent linker, wherein said covalent linker is bonded directly or indirectly to each of the reactive group, the payload moiety, and the cyclodextrin moiety.

[0010a] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0010b] In a further aspect, the present disclosure relates to a compound according to Formula (**Id**):




(**Id**)

wherein:


BA isan antibody or antigen binding fragment thereof;

PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator;


n is an integer from 1 to 30;




is selected from the group consisting of





,





,



,



,


,



,


,



,




,




,




,




,




,




,




,




,




,




,




,




,




,




,





,





,


,


,


,


, and


,

or a pharmaceutically acceptable salt, or stereoisomeric form thereof, or a triazole linkage regioisomer thereof, or mixture of triazole linkage regioisomers thereof, wherein:


each  is a bond to the antibody or antigen binding fragment thereof;

each  is a bond to the payload moiety;

CD is a cyclodextrin moiety; and

R^9 is $–CH_3$ or $–(CH_2)_3N(H)C(O)NH_2$.

[0010c] In a further aspect, the present disclosure relates to a compound according to Formula (**If**):



(**If**)

wherein:


BA is an antibody or antigen binding fragment thereof;

RG is, independently in each instance, a reactive linker residue comprising a succinimide, a triazole, or a fused triazole;

SP^1, **SP^2**, and **SP^3** are each, independently in each instance, absent or a spacer group residue selected from $C_{1\text{-}6}$ alkylene, -NH-, -C(O)-, -$(CH_2$-CH_2-$O)_e$, -NH-CH_2-CH_2-(-O-CH_2-$CH_2)_e$-C(O)-, -C(O)-$(CH_2)_u$-C(O)-, and combinations thereof;

AA^2 is a di-peptide residue;

PEG is a polyethylene glycol residue;

PAB is , wherein the  indicates the atom through which the PAB is bonded to the adjacent groups in the formula;

CD is a cyclodextrin moiety;

e is an integer from 0 to 4;

u is an integer from 1 to 8;

subscript **n** is an integer from 1 to 30;

subscript **m** is an integer from 0 to 5;


subscript **q** is an integer from 0 to 5;;;

subscript **p** is 0 or 1; and


PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator.

[0010d] In a further aspect, the present disclosure relates to a compound according to either

(i) formula (**IIb1**) or (**IIb2**):



or




,


(**IIb1**) (**IIb2**);

or


(ii) a formula selected from:




,



,




, and




,

wherein **RG'** is an alkyne or maleimide;

LL is a trivalent linker that includes:



or



;


SP is, independently in each instance, absent or is a spacer group residue selected from $C_{1\text{-}6}$ alkylene, -NH-, -C(O)-, $-(CH_2\text{-}CH_2\text{-}O)_e$, or $-NH\text{-}CH_2\text{-}CH_2\text{-}(-O\text{-}CH_2\text{-}CH_2)_e\text{-}C(O)-$, and combinations thereof;

e Is an integer from 0 to 4;

PA is the payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator; or

a triazole linkage regioisomer, stereoisomer, or mixture thereof.

[0010e] In a further aspect, the present disclosure relates to a compound according to Formula (**IId**):




(**IId**)


wherein:

RG' is an alkyne or maleimide;


PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator; and




is selected from the group consisting of




,




,




,




,




,




,




,




,




,




,



,



, and



;


or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or a regioisomer thereof, or mixture of regioisomers thereof,

CD is a cyclodextrin residue;

R^9 is $–CH_3$ or $–(CH_2)_3N(H)C(O)NH_2$; and

each  is a bond to the payload moiety.

[0010f] In a further aspect, the present disclosure relates to a compound according to Formula (**IIf**):



(**IIf**)

wherein:


RG' is an alkyne or maleimide;

RG is a reactive group residue comprising a succinimide, a triazole, or a fused triazole;

SP^1, **SP^2**, and **SP^3** are each, independently in each instance, absent or a spacer group residue selected from C_{1-6} alkylene, -NH-, -C(O)-, $-(CH_2-CH_2-O)_e$, $-NH-CH_2-CH_2-(-O-CH_2-CH_2)_e-C(O)-$, $-C(O)-(CH_2)_u-C(O)-$, and combinations thereof;

AA^2 is a di-peptide residue;

PEG is a polyethylene glycol residue;

PAB is , wherein the  indicates the atom through which the PAB is bonded to the adjacent groups in the formula;

CD is a cyclodextrin residue;

subscript **m** is an integer from 0 to 5;

subscript **p** is 0 or 1;

subscript **q** is an integer from 0 to 5; and

e is an integer from 0 to 4;

u is an integer from 1 to 8;

PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator.

[**0010g**] In a further aspect, the present disclosure relates to a linker-payload compound comprising the compound as defined herein bonded to another linker.

[**0010h**] In a further aspect, the present disclosure relates to a linker-payload compound comprising the compound as defined herein wherein the payload moiety is bonded to an oxygen or a primary or secondary nitrogen of the covalent linker.

[**0010i**] In a further aspect, the present disclosure relates to an antibody-drug-conjugate comprising the compound or the linker-payload compound as defined herein bonded to an antibody, or an antigen binding fragment thereof.

[0011] In another example, set forth herein is an antibody-drug conjugate having a compound, above, bonded to an antibody or an antigen binding fragment thereof.

[0012] In another example, set forth herein is a method of treating a disease, condition, or disorder in a patient in need thereof including administering to the patient a compound set forth herein.

[**0012a**] In a further aspect, the present disclosure relates to use of a compound or pharmaceutical composition as defined herein in the manufacture of a medicament for treating a proliferative disease, a metabolic disease, inflammation, or a neurodegenerative disease in a subject; wherein the payload moiety is a therapeutic agent for treating a proliferative disease.

[**0012b**] In a further aspect, the present disclosure relates to use of a compound or pharmaceutical composition as defined herein in the manufacture of a medicament for the treatment of a disease, disorder, or condition in a subject, where the disease, disorder, or condition is a proliferative disease or inflammation; and wherein the payload moiety is a therapeutic agent for treating a proliferative disease or a therapeutic agent for treating inflammation.

[**0012c**] In a further aspect, the present disclosure relates to use of a compound or pharmaceutical composition as defined herein in the manufacture of a medicament for the treatment of a proliferative disease in a subject; wherein the payload moiety is a therapeutic agent for treating a proliferative disease.

[**0012d**] In a further aspect, the present disclosure relates to use of a compound or pharmaceutical composition as defined herein in the manufacture of a medicament for the treatment of a metabolic disease in a subject; wherein the payload moiety is a therapeutic agent for treating a metabolic disease.

[**0012e**] In a further aspect, the present disclosure relates to use of a compound or pharmaceutical composition as defined herein in the manufacture of a medicament for the treatment of inflammation in a subject; wherein the payload moiety is a therapeutic agent for treating inflammation.

[**0012f**] In a further aspect, the present disclosure relates to use of a compound or pharmaceutical composition as defined herein in the manufacture of a medicament for the treatment of a neurodegenerative disease in a subject; wherein the payload moiety is a therapeutic agent for treating a neurodegenerative disease.

[**0012g**] In a further aspect, the present disclosure relates to a method of preparing the compound as defined herein comprising the step of contacting the antibody or antigen binding fragment thereof with the compound as defined herein under conditions suitable for forming a bond between the antibody or antigen binding fragment thereof and the compound.

[0013] In a further example, set forth herein is a method of preparing an antibody-drug conjugate including the step of contacting a binding agent with a linker-payload compound set forth herein under conditions suitable for forming a bond between the binding agent and the linker-payload compound.

[0013a] In a further aspect, the present disclosure relates to a process for preparing an antibody-drug-conjugate comprising reacting the linker-payload compound as defined herein with an antibody, or an antigen binding fragment thereof.

BRIEF DESCRIPTIONS OF THE DRAWINGS

[0014] **Figure 1A** shows three different types of payload compounds.


[0015] **Figure 1B** shows a synthetic process for preparing payload compound **1h** or **1i**.

[0016] **Figure 1C** shows a synthetic process for preparing payload compound **1d**.


WHAT IS CLAIMED IS:

1. A compound or a pharmaceutically acceptable salt thereof, wherein

(i) the compound is according to formula (**Ib1**) or (**Ib2**):



or





,


(Ib1) **(Ib2);**


or

(ii) the compound is according to a formula selected from:



,


,




, and


;

or a triazole linkage regioisomer thereof;

wherein **BA** is an antibody or antigen binding fragment thereof;

LL is a trivalent linker that includes:

or ;



SP is absent or is a spacer group residue selected from C_{1-6} alkylene, -NH-, -C(O)-, and $-(CH_2-CH_2-O)_e$, $-NH-CH_2-CH_2-(-O-CH_2-CH_2)_e-C(O)-$, and combinations thereof;

e is an integer from 0 to 4;

n is an integer from 1 to 30; and

PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator.


2. The compound of claim 1, according to formula (**Ib1**) or (**Ib2**):

(**Ib1**) or (**Ib2**),


or a triazole linkage regioisomer; and/or a stereoisomer thereof.

3. The compound of claim 1 according to formula (**Ib3**), (**Ib4**), (**Ib5**), or (**Ib6**):




,

(**Ib3**)




,

(**Ib4**)



, or

(**Ib5**)




,

(**Ib6**)

or a triazole linkage regioisomer thereof.

4. A compound according to Formula (**Id**):




(**Id**)

wherein:


BA isan antibody or antigen binding fragment thereof;

PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator;


n is an integer from 1 to 30;




is selected from the group consisting of




,




,




,




,




,




,




,




,





,





,























,




,




,




,




,




,




,




,




,



,



, and



,

or a pharmaceutically acceptable salt, or stereoisomeric form thereof, or a triazole linkage regioisomer thereof, or mixture of triazole linkage regioisomers thereof, wherein:


each  is a bond to the antibody or antigen binding fragment thereof;

each  is a bond to the payload moiety;

CD is a cyclodextrin moiety; and

R^9 is $–CH_3$ or $–(CH_2)_3N(H)C(O)NH_2$.

5. A compound according to Formula (**If**):



(**If**)

wherein:


BA is an antibody or antigen binding fragment thereof;

RG is, independently in each instance, a reactive linker residue comprising a succinimide, a triazole, or a fused triazole;

SP[1], **SP[2]**, and **SP[3]** are each, independently in each instance, absent or a spacer group residue selected from C_{1-6} alkylene, -NH-, -C(O)-, $-(CH_2-CH_2-O)_e$, $-NH-CH_2-CH_2-(-O-CH_2-CH_2)_e-C(O)-$, $-C(O)-(CH_2)_u-C(O)-$, and combinations thereof;

AA[2] is a di-peptide residue;

PEG is a polyethylene glycol residue;

PAB is , wherein the  indicates the atom through which the PAB is bonded to the adjacent groups in the formula;

CD is a cyclodextrin moiety;

e is an integer from 0 to 4;

u is an integer from 1 to 8;

subscript **n** is an integer from 1 to 30;

subscript **m** is an integer from 0 to 5;







subscript **q** is an integer from 0 to 5;

subscript **p** is 0 or 1; and

PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator.

6. The compound of any one of claims 1-5, wherein **CD** is, independently in each instance, selected from the group consisting of α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin.














7. The compound of any one of claims 4-5, wherein **CD** is, independently in each instance, selected from the group consisting of


,

,

,

,

, and

,


wherein the  indicates the atom through which the **CD** is bonded to the adjacent groups in the formula.

8. The compound of claim 5, wherein RG comprises a triazole or fused triazole.


9. The compound of claim 5, wherein **RG**, independently in each instance, comprises a triazole or a fused triazole.

10. The compound of claim 5, wherein **RG** is, independently in each instance, selected from the group consisting of , , , , , , , , , , , , , , and , wherein the indicates the atom through which the **RG** is bonded to the adjacent groups in the formula.


11. The compound of claim 4, comprising a group selected from the group consisting of




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,







,




,




,



,




, and




or a pharmaceutically acceptable salt, or stereoisomeric form thereof, or a triazole linkage regioisomer thereof, or mixture of triazole linkage regioisomers thereof.

12. The compound of claim 1, wherein LL includes



13. The compound of claim 1, wherein LL includes



14. The compound of any one of claims 1-3 and 5, wherein the spacer group residue is, independently in each instance, selected from the group consisting of C_{1-6} alkylene, -NH-, -C(O)-, $(-CH_2-CH_2-O)_{e,}$ $-NH-CH_2-CH_2-(-O-CH_2-CH_2)_e-C(O)-$, and combinations thereof.

15. The compound of any one of claims 1-3 and 5, wherein any one of subscript **m**, **q**, or **e** is 4.


16. The compound of claim 5, wherein subscript **p** is 1.

17. The compound of any one of claims 1-3 and 5, wherein subscript **n** is 2-4.


18. The compound of any one of claims 1-17, wherein **BA** is an antibody.

19. The compound of any one of claims 1-17, wherein the wherein **BA** is an antibody, or an antigen-binding fragment thereof, selective for an antigen selected from the group consisting of AXL, BAFFR, BCMA, BCR-list components, BDCA2, BDCA4, BTLA, BTNL2, BTNL3, BTNL8, BTNL9, C10 or f54, CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR9, CCR10, CD11c, CD137, CD138, CD14, CD168, CD177, CD19, CD20, CD209, CD209L, CD22, CD226, CD248, CD25, CD27, CD274, CD276, CD28, CD30, CD300A, CD33, CD37, CD38, CD4, CD40, CD44, CD45, CD46, CD48, CD5, CD52, CD55, CD56, CD59, CD62E, CD68, CD69, CD70, CD74, CD79a, CD79b, CD8, CD80, CD86, CD90.2, CD96, CLEC12A, CLEC12B, CLEC7A, CLEC9A, CR1, CR3, CRTAM, CSF1R, CTLA4, CXCR1/2, CXCR4, CXCR5, DDR1, DDR2, DEC-205, DLL4, DR6, FAP, FCamR, FCMR, FcR's, Fire, GITR, HHLA2, HLA class II, HVEM, ICOSLG, IFNLR1, IL10R1, IL10R2, IL12R, IL13RA1, IL13RA2, IL15R, IL17RA, IL17RB, IL17RC, IL17RE, IL20R1, IL20R2, IL21R, IL22R1, IL22RA, IL23R, IL27R, IL29R, IL2Rg, IL31R, IL36R, IL3RA, IL4R, IL6R, IL5R, IL7R, IL9R, Integrins, LAG3, LIFR, MAG/Siglec-4, MMR, MSR1, NCR3LG1, NKG2D, NKp30, NKp46, PDCD1, PROKR1, PVR, PVRIG, PVRL2, PVRL3, RELT, SIGIRR, Siglec-1, Siglec-10, Siglec-5, Siglec-6, Siglec-7, Siglec-8, Siglec-9, SIRPA, SLAMF7, TACI, TCR-list components/assoc, PTCRA, TCRb, CD3z, CD3, TEK, TGFBR1, TGFBR2, TGFBR3, TIGIT, TLR2, TLR4, TROY, TSLPR, TYRO, VLDLR, VSIG4, and VTCN1.


20. The compound of claim 11, wherein the compound is selected from:


Ab
PA
NH2
OH
n


,


Ab
PA
NH2
OH
n


,


Ab
PA
NH2
OH
n


,


Ab
PA
NH2
OH
n


,


Ab
PA
NH2
OH
HO
HN
N
O
n


,


Ab
PA
NH2
OH
HO
HN
N
O
n


,




n ,




n ,


Ab
PA
n


,



Ab
PA
n


,



Ab
PA
n

,










Ab
PA
n


,


Ab
PA
n


,


Ab
PA
n


,


Ab
PA
n


,


Ab
PA
n


,



n ,




n ,





or stereoisomeric form, triazole linkage regioisomer thereof, mixture of triazole linkage regioisomers thereof, or pharmaceutically acceptable salt thereof,


wherein Ab is the antibody or antigen-binding fragment thereof;
PA is the payload moiety selected from an auristatin, a steroid, and a liver X receptor modulator; and
n is an integer from 1 to 30.


21. The compound of claim 20, wherein the compound is selected from:





















,


,



,

or stereoisomeric form, triazole linkage regioisomer thereof, mixture of triazole linkage regioisomers thereof, or pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising the compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.


23. A compound according to either

(i) formula (**IIb1**) or (**IIb2**):



(**IIb1**)


or




(**IIb2**);

or


(ii) a formula selected from:




,



,




, and




,

wherein **RG'** is an alkyne or maleimide;

LL is a trivalent linker that includes:



or



;


SP is, independently in each instance, absent or is a spacer group residue selected from C_{1-6} alkylene, -NH-, -C(O)-, $-(CH_2-CH_2-O)_e$, or $-NH-CH_2-CH_2-(-O-CH_2-CH_2)_e-C(O)-$, and combinations thereof;

e Is an integer from 0 to 4;

PA is the payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator; or


a triazole linkage regioisomer, stereoisomer, or mixture thereof.

24. The compound of claim 23, according to formula (**IIb3**), (**IIb4**), (**IIb5**), or (**IIb6**):




,

(**IIb3**)




,

(**IIb4**)



, or

(**IIb5**)




,

(**IIb6**)

or a triazole linkage regioisomer thereof, or a mixture of triazole linkage regioisomers thereof.

25. A compound according to Formula (**IId**):




(**IId**)


wherein:

RG' is an alkyne or maleimide;


PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator; and




is selected from the group consisting of




,




,




,




,




,




,




,




,





,



,


,


, and


;


or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or a regioisomer thereof, or mixture of regioisomers thereof,

CD is a cyclodextrin residue;

R^9 is $–CH_3$ or $–(CH_2)_3N(H)C(O)NH_2$; and

each  is a bond to the payload moiety.

26. A compound according to Formula (**IIf**):



(**IIf**)

wherein:


RG' is an alkyne or maleimide;

RG is a reactive group residue comprising a succinimide, a triazole, or a fused triazole;

SP[1], **SP[2]**, and **SP[3]** are each, independently in each instance, absent or a spacer group residue selected from C_{1-6} alkylene, -NH-, -C(O)-, $-(CH_2-CH_2-O)_e$, $-NH-CH_2-CH_2-(-O-CH_2-CH_2)_e-C(O)-$, $-C(O)-(CH_2)_u-C(O)-$, and combinations thereof;

AA[2] is a di-peptide residue;

PEG is a polyethylene glycol residue;

PAB is , wherein the  indicates the atom through which the PAB is bonded to the adjacent groups in the formula;

CD is a cyclodextrin residue;

subscript **m** is an integer from 0 to 5;

subscript **p** is 0 or 1;

subscript **q** is an integer from 0 to 5; and





e is an integer from 0 to 4;



u is an integer from 1 to 8;

PA is a payload moiety selected from a residue of an auristatin, a steroid, and a liver X receptor modulator.

27. The compound of any one of claims 25-26, wherein **CD** is, independently in each instance, selected from the group consisting α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin.





28. The compound of any one of claims 25-26, wherein **CD** is, independently in each instance, selected from the group consisting of





,

,

,

,


, and 
,

wherein the  indicates the atom through which the **CD** is bonded to the adjacent groups in the formula.


29. The compound of any one of claims 23-24 and 26, wherein **RG'** is an alkyne.


30. The compound of any one of claims 23-24 and 26, wherein **RG'** is, independently in each instance, selected from the group consisting of 
,

,

,

,


,

,

, and

,

wherein the  indicates the atom through which the **RG'** is bonded to the adjacent groups in the formula.


31. The compound of claim 25, comprising a group selected from the group consisting of


,



,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,



,




or a pharmaceutically acceptable salt, stereoisomeric form thereof, a triazole linkage regioisomer thereof, or a mixture of triazole linkage regioisomers thereof;

wherein:


each  is a bond to the payload moiety.

32. The compound of claim 23, wherein

-**LL**- includes





33. The compound of claim 23, wherein -**LL**- includes



.

34. The compound of claim 26, wherein


-AA²- is  or 

35. The compound of claim 23 or 26, wherein the spacer group residue is, independently in each instance, selected from the group consisting of C_{1-6} alkylene, -NH-, -C(O)-, $(-CH_2-CH_2-O)_e$, $-NH-CH_2-CH_2-(-O-CH_2-CH_2)_e-C(O)-$, and combinations thereof.


36. The compound of claim 26, wherein any one of subscript **m** or **q** is 4.

37. The compound of claim 26, wherein subscript **p** is 1.


38. The compound of claim 31, wherein the compound is:




,




,




,




,




,




,



,



,



,

or a stereoisomeric form thereof, a triazole linkage regioisomer thereof, or a mixture of triazole linkage regioisomers thereof.

39. A method of preparing the compound of claim 1 comprising the step of contacting the antibody or antigen binding fragment thereof with the compound according to any one of claims 23-38 under conditions suitable for forming a bond between the antibody or antigen binding fragment thereof and the compound.

40. A linker-payload compound comprising the compound of any one of claims 23-38 bonded to another linker.

41. A linker-payload compound comprising the compound of any one of claims 23-38, wherein the payload moiety is bonded to an oxygen or a primary or secondary nitrogen of the covalent linker.

42. An antibody-drug-conjugate comprising the compound of any one of claims 23-38 or the linker-payload compound of any one of claims 40-41 bonded to an antibody, or an antigen binding fragment thereof.

43. Use of a compound or pharmaceutical composition of any of claims 1-22 in the manufacture of a medicament for treating a proliferative disease, a metabolic disease, inflammation, or a neurodegenerative disease in a subject; wherein the payload moiety is a therapeutic agent for treating a proliferative disease.

44. Use of a compound or pharmaceutical composition of any of claims 1-22 in the manufacture of a medicament for the treatment of a disease, disorder, or condition in a subject, where the disease, disorder, or condition is a proliferative disease or inflammation; and wherein the payload moiety is a therapeutic agent for treating a proliferative disease or a therapeutic agent for treating inflammation.

45. Use of a compound or pharmaceutical composition of any of claims 1-22 in the manufacture of a medicament for the treatment of a proliferative disease in a subject; wherein the payload moiety is a therapeutic agent for treating a proliferative disease.

46. Use of a compound or pharmaceutical composition of any of claims 1-22 in the manufacture of a medicament for the treatment of a metabolic disease in a subject; wherein the payload moiety is a therapeutic agent for treating a metabolic disease.









47. Use of a compound or pharmaceutical composition of any of claims 1-22 in the manufacture of a medicament for the treatment of inflammation in a subject; wherein the payload moiety is a therapeutic agent for treating inflammation.

48. Use of a compound or pharmaceutical composition of any of claims 1-22 in the manufacture of a medicament for the treatment of a neurodegenerative disease in a subject; wherein the payload moiety is a therapeutic agent for treating a neurodegenerative disease.

49. The compound of claim 5, wherein any one of subscript **m** and **q** is 4.

50. A process for preparing an antibody-drug-conjugate comprising reacting the linker-payload compound of claim 23 with an antibody, or an antigen binding fragment thereof.

51. The compound of claim 1, wherein **PA** is selected from the group consisting of


;

;

;

;

;

;

; and

;

wherein the  indicates the atom through which the **PA** is bonded to the adjacent groups in the formula.

52. The compound of claim 1 wherein the payload moiety is a residue of an auristatin.

53. The compound of claim 1 wherein the payload moiety is a residue of a steroid.

54. The compound of claim 1 wherein the payload moiety is a residue of a liver X receptor modulator.

55. The compound of claim 23 wherein the payload moiety is a residue of an auristatin.

56. The compound of claim 23 wherein the payload moiety is a residue of a steroid.

57. The compound of claim 23 wherein the payload moiety is a residue of a liver X receptor modulator.

58. The compound of any one of claims 1-23, wherein the antibody or antigen binding fragment thereof is a glutaminyl-modified antibody.

59. The compound of claim 58, wherein the glutaminyl-modified antibody is an antibody modified with an azido-polyethylene glycol-primary amine compound.

60. The compound of claim 1, wherein the antibody or antigen binding fragment thereof is an antibody conjugated to a primary amine compound at a glutamine residue, and LL is bonded to BA through said primary amine compound.

61. The compound of claim 60, wherein the primary amine compound comprises a divalent PEG group.